Aspire Growth Partners LLC Invests $592,000 in Pfizer Inc. (NYSE:PFE)

Aspire Growth Partners LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 22,333 shares of the biopharmaceutical company’s stock, valued at approximately $592,000.

Other large investors have also added to or reduced their stakes in the company. Nordea Investment Management AB increased its position in shares of Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after purchasing an additional 1,080,822 shares during the period. Parsons Capital Management Inc. RI raised its position in shares of Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after buying an additional 159,984 shares in the last quarter. Mcdonald Partners LLC lifted its holdings in shares of Pfizer by 9.9% during the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock worth $2,926,000 after acquiring an additional 9,963 shares during the period. Merit Financial Group LLC lifted its holdings in shares of Pfizer by 60.8% during the 4th quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company’s stock worth $3,395,000 after acquiring an additional 48,397 shares during the period. Finally, Pensionfund Sabic boosted its position in shares of Pfizer by 41.7% during the 4th quarter. Pensionfund Sabic now owns 85,000 shares of the biopharmaceutical company’s stock worth $2,255,000 after acquiring an additional 25,000 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent analyst reports. UBS Group upped their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price on the stock. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $24.19 on Friday. The business has a 50-day moving average of $24.34 and a 200-day moving average of $25.78. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $137.19 billion, a price-to-earnings ratio of 17.16, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the business earned $0.82 EPS. The company’s revenue was down 7.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.11%. Pfizer’s payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.